title: The codon for the methionine at position 129 (M129) in the human prion protein provides an alternative initiation site for translation and renders individuals homozygous for M129 more susceptible to prion disease.
abstract: Single amino-acid substitutions in the prion protein have been found to lead to resistance or susceptibility to amyloid fibril formation. In humans, the presence of methionine at position 129 in the prion protein results in increased susceptibility to prion disease, while the presence of valine at that position appears to be protective. It is hypothesized that the codon for M129 is an alternative initiation site for translation, which results in a truncated molecule that is missing the first 128 amino acids, including the signal peptide. This N-terminal truncated form of the prion molecule will not be transported to the extracellular space and thus will accumulate in the cytosol where it is more susceptible to fibril formation and aggregation; this aggregation could hinder normal degradation processes and cause disease. The results of experimental studies on truncated prion molecules support this hypothesis. To test the hypothesis, a gene segment, which when transcribed would result in a prion molecule starting at methionine 129, could be introduced into a convenient experimental animal to see if there is increased incidence of prion disease. Or, fibrils from the brains of affected M129/M129 homozygous individuals could be isolated and the molecules in the fibrils analyzed to determine the identity of the N-terminal amino acid(s). We predict that those isolates will have a preponderance of molecules that start with the methionine at position 129 in the intact protein.
authors.affiliation: Marine Science Institute, College of Science, University of the Philippines Diliman, 1101 Quezon City, Philippines.
authors.forename: G P
authors.initials: GP
authors.lastname: Concepcion
authors.forename: E A
authors.initials: EA
authors.lastname: Padlan
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D002986:Clinical Trials as Topic; D018387:Codon, Initiator / Q000235:genetics; D004252:DNA Mutational Analysis / Q000379:methods; D019317:Evidence-Based Medicine; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics; D005820:Genetic Testing / Q000379:methods*; D006720:Homozygote; D006801:Humans; D015994:Incidence; D008715:Methionine / Q000235:genetics*; D008957:Models, Genetic; D011110:Polymorphism, Genetic; D017096:Prion Diseases / Q000201:enzymology* / Q000453:epidemiology* / Q000235:genetics; D011328:Prions / Q000235:genetics*; D014176:Protein Biosynthesis / Q000235:genetics; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
chemical_list: D018387:Codon, Initiator; D011328:Prions; D008715:Methionine